| Ytd | -72.40% | |
| 1y | -95.09% |
| Open | 1.93 | Prev Close | 1.92 | Low | 1.86 | High | 1.97 | Mkt Cap | 4.18M |
| Vol | 14.61K | Avg Vol | 186.61K | EPS | -2.83 | P/E | N/A | Forward P/E | -0.29 |
| Beta | -1.21 | Short Ratio | 0.10 | Inst. Own | 4.71% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-18 | 50-d Avg | 1.70 | 200-d Avg | 8.28 | 1yr Est | 11.50 |
GRI News
Video webcast now available here
LA JOLLA, CA, Aug. 24, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Compa
Bitcoin jumped 4.6% to $72,475.25 – a roughly 12% gain over the past two days after the digital asse
Gainers Neuronetics (NASDAQ:STIM) shares moved upwards by 34.1% to $2.91 during Tuesday's regul
Ingevity Corporation (NYSE: NGVT) today announced it has published its [url="]2025 Sustainability Re
Ingram Micro today released its 2025 Sustainable Impact Report, detailing the company's progress mad
Williams (NYSE: WMB) today released its 2025 Sustainability Report, highlighting its environmental,
Gainers Advanced Biomed (NASDAQ:ADVB) shares rose 24.1% to $6.24 during Monday's pre-market ses
Today, Banner Bank released its 2025 Corporate Responsibility Report. The report identifies ongoing
Asbury Automotive Group, Inc. (NYSE: ABG), one of the largest automotive retail and service companie
Luxshare Precision Releases 2025 Sustainability Report PR Newswire NEW YORK, June 23, 2026
CROWN HOLDINGS ANNOUNCES PUBLICATION OF ITS 2025 SUSTAINABILITY REPORT "DELIVERING SUSTAINABILITY",
Designation highlights significant regulatory milestone and provides a potential pathway to seven ye
Designation highlights significant regulatory milestone and provides a potential pathway to seven ye
The Toro Company (NYSE: TTC), a leading global provider of solutions for the outdoor environment, to
Wall Street analysts updated views on notable stocks. See changes on analyst ratings page. Price tar
Ascendiant Capital analyst Edward Woo maintains GRI Bio (NASDAQ:GRI) with a Buy and lowers the pr
Live webcast fireside chat with Marc Hertz, PhD, Chief Executive Officer, on Wednesday, May 20, 2026
GRI Bio (NASDAQ:GRI) reported quarterly losses of $(1.61) per share which missed the analyst consens
Phase 2a data show zero cough and 60% lower treatment-related diarrhea than placebo despite higher n
Issued claims further strengthen global intellectual property portfolio supporting immune cell modul
Issued claims further strengthen global intellectual property portfolio supporting immune cell modul
Ascendiant Capital analyst Edward Woo maintains GRI Bio (NASDAQ:GRI) with a Buy and lowers the pr
Access the “What This Means” segment here
– Live video webcast on Wednesday, February 11 th at 1:00 PM EST
GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company ad
Company reported $8.2 million in cash and cash equivalents at December 31, 2025 and raised additiona
Met its primary endpoint, demonstrating favorable safety and tolerabilityMet multiple secondary endp
GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company ad
New immune profiling data confirms disease-modifying mechanism, reinforces earlier signals of fibros
GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company adv
GRI Bio shared promising data from a Phase 2a trial for idiopathic pulmonary fibrosis, a chronic lun
Study met its primary endpoint demonstrating that GRI-0621 was well tolerated over 12 weeks of treat
GRI Bio, Inc. (the "Company") has received topline data from the Phase 2a GRI-0621-IPF-02 cl
Ascendiant Capital analyst Edward Woo maintains GRI Bio (NASDAQ:GRI) with a Buy and raises the pr